Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole plus Caspofungin for Invasive Fungal Infections
NCT00238355Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Aug 2003
- Primary completion
- Jun 2008
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of caspofungin, voriconazole in invasive fungal infection (IFI), sponsored by OHSU Knight Cancer Institute. Started Aug 2003; status: terminated.
02
Drugs
caspofunginvoriconazole
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT00238355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00238355.